ArticleJournal of cellular and molecular medicine2021
Comparative genomic analysis of head and body/tail of pancreatic ductal adenocarcinoma at early and late stages.
Article in Journal of cellular and molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Thromboembolic Risks in Pancreatic Ductal Adenocarcinoma: A Review of Anatomical and Clinical Variations.Canadian journal of gastroenterology & hepatology · 2026Review
- Comparative efficacy and safety of NALIRIFOX versus other first-line chemotherapy regimens in metastatic pancreatic ductal adenocarcinoma: a retrospective study.Therapeutic advances in medical oncology · 2026Article
- Synchronous Pancreatic Neoplasms Involving Pancreatic Ductal Adenocarcinoma: A Systematic Review of Case Reports.Journal of personalized medicine · 2025Review
- Impact of Tumor Location on Survival Outcomes in Pancreatic Head Versus Body/Tail Cancer: Institutional Experience.Cancers · 2025Article
- Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX.JAMA oncology · 2025Article
- Comparison of clinical characteristics and prognostic factors in two site-specific categories of ampullary cancer.World journal of gastroenterology · 2024Article
- Comparing clinical and genomic features based on the tumor location in patients with resected pancreatic cancer.BMC cancer · 2024Article
- Microbiota and metabolite alterations in pancreatic head and body/tail cancer patients.Cancer science · 2024Article
- Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biological R2 Definition".Annals of surgical oncology · 2024Article
- Article
- Comparative molecular profiling of pancreatic ductal adenocarcinoma of the head versus body and tail.NPJ precision oncology · 2024Article
- Heterogeneity of weight loss and transcriptomic signatures in pancreatic ductal adenocarcinoma.Journal of cachexia, sarcopenia and muscle · 2024Article
- Splenic Hilar Involvement and Sinistral Portal Hypertension in Unresectable Pancreatic Tail Cancer.Cancers · 2023Article
- Prediction of postoperative recurrence in resectable pancreatic body/tail adenocarcinoma: a novel risk stratification approach using a CT-based nomogram.European radiology · 2023Article
- Factors predicting recurrence after left‑sided pancreatectomy for pancreatic ductal adenocarcinoma.World journal of surgical oncology · 2023Article
- Nomogram for Predicting Distant Metastasis of Pancreatic Ductal Adenocarcinoma: A SEER-Based Population Study.Current oncology (Toronto, Ont.) · 2022Article
- Segmentation of Pancreatic Subregions in Computed Tomography Images.Journal of imaging · 2022Article
- Comment on: "Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancer".Annals of surgical oncology · 2022Article
- Pancreatic headWorld journal of gastrointestinal oncology · 2022Article
- The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.BMC cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal human cancers, can be divided into head and body/tail cancers anatomically. We previously reported a prognostic relevance of tumour location in resectable PDAC. This study aimed to further explore the mechanism underlying the molecular diversity between the head and body/tail of PDACs. We detected tumour genomes in 154 resectable (surgery) and non-resectable (biopsy) PDACs using a next-generation sequencing panel. Wilcoxon's rank test or Fisher's exact test was used for evaluating associations between clinical characteristics, mutation frequency and survival probability between the two cohorts. Compared with pancreatic head cancers, pancreatic body/tail cancers showed significantly more enriched genomic alterations in KRAS (97.1% vs 82.4%, P = 0.004) and SMAD4 (42.0% vs 21.2%, P = 0.008). At early stages (I-II), the SMAD4 mutation rate was significantly higher in pancreatic body/tail cancers than pancreatic head cancers (56.0% vs 26.5%, P = 0.021). At late stages (III-IV), pancreatic body/tail cancers presented significantly higher KRAS mutation rate (100.0% vs 75.8%, P = 0.001), higher frequency of MAPK pathway mutation (100% vs 87.8%, P = 0.040) and lower rates of druggable genomic alterations (30.8% vs 57.6%, P = 0.030) than pancreatic head cancers. Our work points out that pancreatic body/tail cancer seems to be more malignant than pancreatic head cancer at late stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.